Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach
Sadaf Jahan,Neeru Singh Redhu,Arif Jamal Siddiqui,Danish Iqbal,Johra Khan,Saeed Banawas,Mohammed Alaidarous,Bader Alshehri,Shabir Ahmad Mir,Mohd Adnan,Aditya Bhushan Pant,Jahan,Redhu,Siddiqui,Iqbal,Khan,Banawas,Alaidarous,Alshehri,Mir,Adnan,Pant
DOI: https://doi.org/10.3390/pharmaceutics14061123
IF: 6.525
2022-05-25
Pharmaceutics
Abstract:Excitotoxicity is a type of neurodegenerative disorder. It caused by excessive glutamate receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D-aspartate (NMDA) receptors are found in glutamatergic neurons, and their excessive activation is primarily responsible for excitotoxicity. They are activated by both glutamate binding and postsynaptic depolarization, facilitating Ca2+ entry upon activation. Therefore, they are now widely acknowledged as being essential targets for excitotoxicity issues. Molecular docking and molecular dynamics (MD) simulation analyses have demonstrated that nobiletin efficiently targets the binding pocket of the NMDA receptor protein and exhibits stable dynamic behavior at the binding site. In this study, five potential neuroprotectants, nobiletin, silibinin, ononin, ginkgolide B, and epigallocatechin gallate (EGCG), were screened against the glutamate NMDA receptors in humans via computational methods. An in silico ADMET study was also performed, to predict the pharmacokinetics and toxicity profile for the expression of good drug-like behavior and a non-toxic nature. It was revealed that nobiletin fulfills the criteria for all of the drug-likeness rules (Veber, Lipinski, Ghose, Muegge, and Egan) and has neither PAINS nor structural alerts (Brenks). In conclusion, nobiletin demonstrated a possible promising neuroprotectant activities compared to other selected phytochemicals. Further, it can be evaluated in the laboratory for promising therapeutic approaches for in vitro and in vivo studies.
pharmacology & pharmacy